QNCX
Quince Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$31.73
+8.07%Price chart
Sep 16Sep 21Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15
Key dataOct 15, 2026
Open$28.99
From 52W high−96.39%
Volume9000.00
Market cap$32.27M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 15, 2026
Open
$28.99
From 52W high
−96.39%
Volume
9000.00
Market cap
$32.27M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
P/E (TTM)
—
RSI (14)
58.6
MomentumView details →
1D Return
+8.07%
YTD Return
−95.16%
SummaryUpdated Jun 1, 2026
Quince Therapeutics, Inc. (NASDAQ:QNCX) is a biopharmaceutical company founded in 2012 and headquartered in South San Francisco, California. Originally incorporated as Cortexyme, Inc., the company rebranded to Quince Therapeutics in August 2022 following a strategic pivot in its research focus. The company went public in May 2019 and currently operates as a clinical-stage biotechnology firm specializing in precision therapeutics for debilitating and rare diseases, with a particular emphasis on bone-targeting drug delivery technologies.
Similar companies
Latest newsMore news →
Quince Therapeutics said Brendan Hannah resigned as chief operating officer, chief business officer and chief compliance officer, effective October 8, 2026, and appointed Keith Fandrick as his successor.11d agoQuince Therapeutics said Dirk Thye resigned as chief executive officer, chief medical officer and director, effective October 8, 2026, and appointed Brigette Roberts as chief executive officer.11d agoQuince Therapeutics, Inc. announced that its common stock will trade on NASDAQ, INC. under the symbol IRLA effective October 12, 2026.11d ago